title: Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.
authors.affiliation: Department of Psychiatry, University of Kansas School of Medicine-Wichita, Wichita, Kansas, USA.
authors.forename: Sheldon H
authors.initials: SH
authors.lastname: Preskorn
authors.forename: Silvana
authors.initials: S
authors.lastname: Borges-Gonzalez
authors.forename: David
authors.initials: D
authors.lastname: Flockhart
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D001058:Apomorphine / Q000009:adverse effects / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D053961:Azabicyclo Compounds; D002219:Carbamates / Q000627:therapeutic use; D002491:Central Nervous System Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D017277:Drug Approval / Q000331:legislation & jurisprudence* / Q000706:statistics & numerical data*; D004347:Drug Interactions; D000068736:Duloxetine Hydrochloride; D005663:Furans; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000627:therapeutic use; D007192:Indenes / Q000009:adverse effects / Q000627:therapeutic use; D008133:Long QT Syndrome / Q000139:chemically induced; D001523:Mental Disorders / Q000188:drug therapy*; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use; D010755:Organophosphates / Q000627:therapeutic use; D010879:Piperazines / Q000009:adverse effects; D011600:Psychopharmacology / Q000379:methods*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D000928:Antidepressive Agents; D000978:Antiparkinson Agents; D053961:Azabicyclo Compounds; D002219:Carbamates; D002491:Central Nervous System Agents; D005663:Furans; D006993:Hypnotics and Sedatives; D007192:Indenes; D009842:Oligopeptides; D010755:Organophosphates; D010879:Piperazines; D011725:Pyridines; D013449:Sulfonamides; D013876:Thiophenes; C515050:zopiclone; D000069446:Atazanavir Sulfate; C495910:ramelteon; D003577:Cytochrome P-450 Enzyme System; D000068736:Duloxetine Hydrochloride; D001058:Apomorphine; C426859:fosamprenavir